Skip to main content
Top
Published in: Digestive Diseases and Sciences 10/2010

01-10-2010 | Original Article

Trends in the Indication and Method of Liver Biopsy for Hepatitis B and C

Authors: Michael J. Lipp, Lionel S. D’Souza, David J. Clain, Henry C. Bodenheimer Jr., Albert D. Min

Published in: Digestive Diseases and Sciences | Issue 10/2010

Login to get access

Abstract

Background and Aims

Liver biopsy plays a crucial role in assessing inflammation and fibrosis in chronic hepatitis. The aim of this study was to compare the indications and methods for performing a liver biopsy over a 15-year period when there were evolving strategies and increasing therapeutic options for the treatment for chronic hepatitis B (HBV) and C (HCV).

Methods

We reviewed all percutaneous liver biopsies performed at our center from 1992 to 2007 using a pathology database. Variables collected included indication for biopsy, use of real-time ultrasound (US) guidance, and complications associated with the biopsy.

Results

A total of 3,572 total liver biopsies were performed between 1992 and 2007 with a gradual increase in annual liver biopsies from 1992 to 2001. After a peak in 2003, there was a gradual decline in liver biopsies performed. The number of liver biopsies done for HCV peaked in 2003, followed by an annual decrease until 2006, while the number of annual biopsies done for HBV increased during the same period. In addition, the proportion of liver biopsies performed with real-time US-guidance increased steadily since 1997.

Conclusions

Changes in liver biopsy trends at our center may be related to several factors, including the evolving treatment strategies for HCV and HBV. Percutaneous liver biopsies were increasingly performed using real-time US-guidance over the past decade, a change that may reflect practice patterns around the country.
Literature
2.
go back to reference Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.CrossRefPubMed Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982.CrossRefPubMed
3.
go back to reference Strader DB, Wright T, Thomas DL, et al. AASLD practice guidelines—diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147–1171.CrossRefPubMed Strader DB, Wright T, Thomas DL, et al. AASLD practice guidelines—diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147–1171.CrossRefPubMed
4.
go back to reference Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47:760–767.CrossRefPubMed Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47:760–767.CrossRefPubMed
5.
go back to reference Kumar M, Sarin SK, Hissar S, et al. Virologic and histologic features of chronic hepatitis B virus-Infected asymptomatic patients with persistently normal ALT. Gastroenterology. 2008;134:1376–1384.CrossRefPubMed Kumar M, Sarin SK, Hissar S, et al. Virologic and histologic features of chronic hepatitis B virus-Infected asymptomatic patients with persistently normal ALT. Gastroenterology. 2008;134:1376–1384.CrossRefPubMed
6.
go back to reference Sporea I, Popescu A, Sirli R. Why, who and how should perform liver biopsy in chronic liver diseases. World J Gastroenterol. 2008;14(21):3396–3402.CrossRefPubMed Sporea I, Popescu A, Sirli R. Why, who and how should perform liver biopsy in chronic liver diseases. World J Gastroenterol. 2008;14(21):3396–3402.CrossRefPubMed
7.
go back to reference Al Knawy B, Shiffman Mitchell. Percutaneous liver biopsy in clinical practice. Liver Int. 2007;27(9):1166–1173.CrossRefPubMed Al Knawy B, Shiffman Mitchell. Percutaneous liver biopsy in clinical practice. Liver Int. 2007;27(9):1166–1173.CrossRefPubMed
8.
go back to reference Sheela H, Seela S, Caldwell C, et al. Liver biopsy—evolving role in the new millennium. J Clin Gastroenterol. 2005;39:603–610.CrossRefPubMed Sheela H, Seela S, Caldwell C, et al. Liver biopsy—evolving role in the new millennium. J Clin Gastroenterol. 2005;39:603–610.CrossRefPubMed
9.
go back to reference Muir AJ, Trotter JF. A survey of current liver biopsy practices. J Clin Gastroenterol. 2002;35(1):86–88.CrossRefPubMed Muir AJ, Trotter JF. A survey of current liver biopsy practices. J Clin Gastroenterol. 2002;35(1):86–88.CrossRefPubMed
10.
go back to reference Angtuaco TL, Lal SK, Banaad-Omiotek GD, et al. Current liver biopsy practices for suspected parenchymal liver diseases in the United States: the evolving role of radiologists. Am J Gastroenterol. 2002;97(6):1468–1471.CrossRefPubMed Angtuaco TL, Lal SK, Banaad-Omiotek GD, et al. Current liver biopsy practices for suspected parenchymal liver diseases in the United States: the evolving role of radiologists. Am J Gastroenterol. 2002;97(6):1468–1471.CrossRefPubMed
11.
go back to reference Riley TR III. How often does ultrasound marking change the liver biopsy site. Am J Gastroenterol. 1999;94:3320–3322.CrossRefPubMed Riley TR III. How often does ultrasound marking change the liver biopsy site. Am J Gastroenterol. 1999;94:3320–3322.CrossRefPubMed
12.
go back to reference Caturelli E, Giacobbe A, Facciorusso D, et al. Percutaneous biopsy in diffuse liver disease: increasing diagnostic yield and decreasing complication rate by routine ultrasound assessment of puncture site. Am J Gastroenterol. 1996;91:1318–1321.PubMed Caturelli E, Giacobbe A, Facciorusso D, et al. Percutaneous biopsy in diffuse liver disease: increasing diagnostic yield and decreasing complication rate by routine ultrasound assessment of puncture site. Am J Gastroenterol. 1996;91:1318–1321.PubMed
13.
go back to reference The gastroenterology core curriculum, 3rd ed. Gastroenterology. 2007;132(5):2012–2018. The gastroenterology core curriculum, 3rd ed. Gastroenterology. 2007;132(5):2012–2018.
14.
go back to reference National Institutes of Health. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements. 2002;19(3):1–46. National Institutes of Health. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements. 2002;19(3):1–46.
15.
go back to reference National Institutes of Health. Management of hepatitis C. NIH Consens Statement Online. 1997;15(3):1-41. National Institutes of Health. Management of hepatitis C. NIH Consens Statement Online. 1997;15(3):1-41.
16.
go back to reference Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2:87–106.CrossRefPubMed Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States. Clin Gastroenterol Hepatol. 2004;2:87–106.CrossRefPubMed
17.
go back to reference Lok AS, McMahon BJ. Practice guidelines committee, AASLD. Chronic hepatitis B. Hepatology. 2001;34(6):1225–1241.CrossRefPubMed Lok AS, McMahon BJ. Practice guidelines committee, AASLD. Chronic hepatitis B. Hepatology. 2001;34(6):1225–1241.CrossRefPubMed
19.
go back to reference Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6(12):1315–1341.CrossRefPubMed Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6(12):1315–1341.CrossRefPubMed
20.
21.
Metadata
Title
Trends in the Indication and Method of Liver Biopsy for Hepatitis B and C
Authors
Michael J. Lipp
Lionel S. D’Souza
David J. Clain
Henry C. Bodenheimer Jr.
Albert D. Min
Publication date
01-10-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 10/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-010-1337-8

Other articles of this Issue 10/2010

Digestive Diseases and Sciences 10/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.